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Summary 
Cytotoxic T lymphocytes (CTL) are thought to contribute to viral clearance and liver cell injury 
during hepatitis B virus (HBV) infection. Using a strategy involving the in vitro stimulation 
of peripheral blood mononuclear cells (PBMC) with HBV-derived synthetic peptides containing 
HLA-A2.1, -A31, and -Aw68 binding motifs, we have previously described CTL responses to 
several epitopes within the HBV nudeocapsid and envelope antigens in patients with acute hepa- 
titis. In this study we define six HLA-A2-restricted CTL epitopes located in the highly conserved 
reverse transcriptase and RNase H  domains of the viral polymerase protein, and we show that 
the CTL response to polymerase is polyclonal, multispecific, and mediated by CD8 + T  cells 
in patients with acute viral hepatitis, but that it is not detectable in patients with chronic HBV 
infection or uninfected healthy blood donors. Importantly, the peptide-activated CTL recognize 
target cells that express endogenously synthesized polymerase protein, suggesting that these pep- 
tides represent naturally processed viral epitopes. DNA sequence analysis of the viruses in pa- 
tients who did not respond to peptide stimulation indicated that CTL nonresponsiveness was 
not due to infection by viral variants that differed in sequences from the synthetic peptides. CTL 
specific for one of the epitopes were unable to recognize several naturally occurring viral variants, 
except at high peptide concentration, underlining the HBV subtype specificity of this response. 
Furthermore, CTL responses against polymerase, core, and envelope epitopes were detectable 
for more than a year after complete clinical recovery and seroconversion, reflecting either the 
persistence of trace amounts of virus or the presence of long lived memory CTL in the absence 
of viral antigen.  Finally,  we demonstrated that  wild type viral DNA  and RNA  can persist 
indefinitely, in trace quantities, in the serum and PBMC after complete clinical and serological 
recovery, despite a concomitant, vigorous, and sustained polyclonal CTL response. Since viral 
persistence is not due to escape from CTL recognition under these conditions, the data suggest 
that HBV may retreat into immunologically privileged sites from which it can seed the circula- 
tion and reach CTL-inaccessible  tissues,  thereby maintaining the CTL response in apparently 
cured individuals and, perhaps, prolonging the liver disease in patients with chronic hepatitis. 
T 
he  hepatitis  B  virus  (HBV) 1  is  a  noncytopathic 
DNA virus with a small, circular DNA genome that 
encodes several envelope (preS1, preS2, HBsAg), nucleocapsid 
1  Abbreviations used in this paper: ALT, alanine  aminotransferase;  B-I_CL, 
B lymphoblastoid cell lines; HBcAg, HBeAg, HBsAg, hepatitis B core, 
envelope, or surface antigen, respectively; HBV, HCV,  hepatitis B or C 
virus, respectively; pol, polymerase; Vpol, vaccinia virus construct encoding 
the HBV polymerase protein. 
(HBcAg, HBeAg), transactivating (X), and polymerase (pol) 
proteins and causes acute and chronic liver disease and hepa- 
tocellular carcinoma (1). It is thought that the immune re- 
sponse to one or more of these virus proteins is responsible 
for viral clearance and liver cell injury during HBV infec- 
tion, and that HLA class I-restricted CTL play a major role 
in these events.  In support of this hypothesis, we have re- 
cently shown that murine HBV envelope-specific  CTL can 
cause severe acute liver disease when they are injected into 
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CTL can also inhibit HBV gene expression noncytolytically 
in these animals (3),  suggesting that virus inactivation can 
occur intracellularly without killing the infected cell. If the 
same events occur in the human liver during acute viral hepa- 
titis, then the tissue-sparing effects of this aspect of the anti- 
viral immune response  could be substantial. 
We have shown that patients with acute viral hepatitis 
mount a vigorous CTL response to multiple epitopes in the 
viral nucleocapsid (4-7) and envelope (8) proteins, whereas 
patients with chronic hepatitis and uninfected healthy indi- 
viduals  do not. Until now, however,  the CTL response  to 
the viral polymerase protein has not been defined. The HBV 
polymerase is a 93-kD protein that contains three functional 
domains that perform crucial functions in the viral life cycle: 
the terminal protein, reverse transcriptase,  and RNase H (9). 
As such, it must be expressed very early during infection and, 
because it principally functions as an enzyme, it does not need 
to be expressed in very large amounts, unlike the structural 
proteins of the virus.  Like other viral polymerases (10, 11), 
therefore, it would not be surprising if the HBV polymerase 
is a prominent target of the immune response,  especially at 
the level of the CTL. More specifically,  a CTL response against 
this protein could abort an incipient infection before it could 
spread.  Indeed, this scenario  is compatible with the well- 
known subclinical, self-limited outcome of most HBV infec- 
tions in adults. 
In this article,  we demonstrate that acutely infected pa- 
tients with clinically obvious viral hepatitis develop an HLA 
class I-restricted CTL response to multiple epitopes in the 
conserved functional domains of the HBV polymerase pro- 
tein, while persistently infected patients with chronic hepa- 
titis and normal uninfected controls do not. We also demon- 
strate that viral DNA can persist in the serum and PBMC, 
and that the CTL response  to several polymerase, envelope, 
and nucleocapsid epitopes can persist for more than a year 
following complete clinical recovery and seroconversion. The 
data suggest that persistence of the CTL response after recovery 
could reflect  either  the  continued presence  of long-lived 
memory cells in the absence of antigen, or the persistence 
of trace  amounts of wild-type virus  in  immunologicaUy 
privileged compartments that can seed the peripheral blood 
with virus and maintain the CTL response long after clear- 
ance of viral antigens from the blood. 
Materials  and Methods 
Patient Population.  Nine HLA-A2  + patients with acute hepa- 
titis B, 9 HLA-A2  § patients with chronic hepatitis B, and 10 
HLA-A2  + healthy, uninfected subjects were studied. The diagnosis 
of acute hepatitis B was based on clinical and biochemical evidence 
of acute liver injury according to standard diagnostic criteria, that 
is, jaundice and elevated  values of alanine amino transferase  (ALT) 
activity at least 20-fold greater than the upper limit of normal, 
together with serological evidence of acute HBV infection, that 
is, hepatitis B surface antigen  (HBsAg), hepatitis B e antigen 
(HBeAg) and IgM anti-HBc antibody (IgM HBc-Ab), and the ab- 
sence of serologic evidence  of  hepatitis 8 or hepatitis C virus (HCV) 
infection (Abbott Laboratories, North Chicago, IL). Six of  the nine 
patients recovered completely,  with normalization of serum trans- 
aminases and clearance  of HBsAg and HBeAg within 4 mo of ini- 
tial diagnosis; the remaining three patients were lost to follow-up 
after their initial clinic visit. All patients with chronic hepatitis 
B were repeatedly serologically  positive for HBsAg for >6 mo and 
displayed  mildly to moderately  elevated  serum ALT activity.  Normal 
controls had no clinical history of HBV infection and were sero- 
logically negative for all HBV markers. All subjects studied were 
repeatedly negative for antibodies to HCV and HIV. The study 
protocol was approved by the Human Subjects Committee at the 
Scripps Clinic and Research Foundation. 
Synthetic Peptides, HBV Antigens, and Tetanus Toxoid.  A panel 
of  9 and 10 residue  peptides  containing  the HLA-A2.1  binding motif, 
that is, a leucine, methionine, or isoleucine in the second position 
and a valine, isoleucine, or leucine at the COOH terminus, were 
purchased from Chiron Mimotopes Peptide Systems  (Clayton, Vic- 
toria, Australia). Lyophilized peptides were reconstituted at 20 
mg/ml in DMSO (Malinckrodt Inc., Paris, KY) and diluted to 1 
mg/ml with RPMI-1640 medium (Gibco Laboratories, Grand Is- 
land, NY). rHBcAg was obtained from bacterial extracts of Esche- 
richia coli as previously described (12), and tetanus toxoid protein 
was purchased from Connaught Laboratories (Swiftwater, PA). 
HLA-binding Aflinity Analysis of Peivtides.  The HLA-A2.1 binding 
affinity of the peptides was determined by competitive binding 
studies with radiolabeled HBVcore18-27 peptide FLPSDYFPSV as 
previously  described (13). Purified  class I molecules  were incubated 
at room temperature with various doses of the test peptides, to- 
gether with 5-10 nM of the labeled peptide and 1/~M human 
B2-microglobulin (Calbiochem Corp., La Jolla, CA). After 48 h, 
class I-peptide complexes were separated from free peptide by gel 
filtration. Class I-bound and free radioactivity was measured, and 
the doses of test peptides yielding 50% inhibition of the binding 
of the labeled peptide (IC50) were calculated. 
Recombinant Expression Vectors.  A recombinant vaccinia virus 
construct that encodes the HBV polymerase protein (Vpol) was 
produced by insertion of a 2766-bp fragment representing nucleo- 
tides 2290-1874 of the HBV genome (ayw subtype) into the SmaI 
site of the pSC11 vector by standard techniques as previously de- 
scribed (14). Stable transfectants that express HBpolAg were pro- 
duced by transfection of EBV-transformed B lymphoblastoid cell 
lines (B-LCL) with a panel of EBV-based expression vectors that 
contain the corresponding coding regions of the HBV ayw sub- 
type (15). 
Stimulation of PBMC with Synthetic Peptides and rHBc.Ag.  PBMC 
from patients and normal donors were separated on Ficoll-Histo- 
paque density gradients (Sigma Chemical Co., St. Louis, MO), 
washed three times in HBSS (Gibco BRL Laboratories, Gaithers- 
burg, MD), resuspended  in RPMI-1640 (Gibco Laboratories)  sup- 
plemented with t-glutamine (2 mM), gentamycin (10 #M),  and 
10% heat-inactivated human AB serum, and plated in a 24-well 
plate at 4  x  106 cells/well, rHBcAg (Biogen, Cambridge, MA) 
was added to the cell cultures at 1/zM and the synthetic peptides 
at 10/~M. In some of the experiments with healthy uninfected 
blood donors, rHBcAg was either omitted or replaced by 10/~M 
tetanus toxoid since these individuals  have  not been exposed to HBV 
previously and do not benefit from rHBcAg-induced T cell help. 
On days 3 and 10, 1 ml of RPMI with 10% human AB serum 
and riD2 (Hoffmann-La  Roche, Inc., Nutley, NJ) at 10 U/ml final 
concentration was added to each well. On day 7, the cultures were 
restimulated with peptide, rll~2, and irradiated (3,000 rad) autolo- 
gous feeder cells, and they were tested for cytotoxic activity on 
day 14. Selected cultures that displayed  peptide-specific cytolytic 
activity were separated into CD4 + and CD8 + populations by pan- 
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Clara,  CA) and restimulated as described above. 
Generation of  HBV-specific CTL Lines and Clones.  CTL lines were 
established  as described  above and enriched in highly cytotoxic 
CD8 + CTLs by cloning at 10 and 3 cells/well in 96-well micro- 
titer plates in the presence of 0.05 #M CD3-specific mAb (Coulter 
Immunology, Hialeah, FL), rib2 (100 U/ml), and 10  s irradiated 
(3,000 rad) allogeneic PBMC. HBV-specific clones were established 
by cloning at 1 and 0.3 cells/well in the same way. Growing cul- 
tures were tested for cytotoxic activity against peptide-primed target 
cells on day 17, and cytotoxic lines and clones were expanded in 
24-well plates  and restimulated every 10 d. 
Target Cell Lines.  Autologous and allogeneic EBV-transformed 
B-LCL were either purchased from The American  Society for 
Histocompatibility and Immunogenetics (Boston, MA) or estab- 
lished  from our own pool of patients and normal donors as de- 
scribed (15). For most studies, JY cell targets (HLA-A2.1, B7, Cw7) 
were used.  All target cells were maintained in RPMI with 10% 
(vol/vol) heat-inactivated FCS (GIBCO BILL). 
Cytotoxicity Assay.  Target cells consisted either of (a) allogeneic 
HLA-matched and mismatched B-LCL incubated overnight with 
synthetic peptides at 10 #M; (b) stable B-LCL transfectants as de- 
scribed  above; or (c) B-LCL infected with recombinant vaccinia 
viruses. Vaccinia-infected targets were prepared by infection of 106 
cells at 50 PFU/cell on a rocking plate at room temperature for 
1 h followed by a single wash and overnight incubation at 37~ 
Target cells were then labeled with 100 #Ci of S*Cr (Amersham 
Corp., Arlington Heights, IL) for 1 h and washed four times with 
HBSS. Cytolytic activity was determined in a standard 4-h S*Cr 
release assay using U-bottomed 96-well  plates  containing 5,000 
targets/well. Stimulated PBMC from patients and normal controls 
were tested at E/T ratios of 50:1. All assays were performed in 
duplicate.  Percent cytotoxicity was determined from the formula: 
100  x  [(experimental release  -  spontaneous release)/(maximum 
release -  spontaneous release)]. Maximum release was determined 
by lysis of targets by detergent (1% Triton X-100; Sigma Chemical 
Co.). Spontaneous release was <20% of maximal release in all assays. 
The assay was considered positive if the specific SlCr release from 
target cells containing antigen was  t>15%  higher than the non- 
specific S~Cr release from antigen-negative target cells,  and the 
nonspecific  lysis was <15%  of maximum. 
Flow Cytometry.  0.5-1.0  x  106  cells  to  be  analyzed  were 
washed once in PBS with 5% BSA and 0.02% sodium azide. The 
pelleted cells were then stained with a fluorescent probe-conjugated 
anti-CD4 and anti-CD8 mAB (Leu3a, Leu2a) and a similarly  la- 
beled control antibody (Becton Dickinson & Co., Mountain View, 
CA) for 30 min at 4~  After three washes in PBS with 5% BSA 
and 0.02%  sodium azide,  cells were analyzed with a flow cyto- 
meter (FACScan|  Becton Dickinson &  Co.). 
HLA Typing.  HLA typing of PBMC from patients and normal 
donors was performed by complement microcytotoxicity by use 
of HLA typing trays purchased form One Lambda (Los Angeles, 
CA). 
Extraction of DNA and RNA from Serum and PBMC.  HBV 
DNA was isolated from serum and PBMC by proteinase K diges- 
tion and phenol chloroform extraction exactly as previously de- 
scribed  (8,  16). HBV RNA was extracted from PBMC samples 
that were positive for HBV DNA by use of the acid guanidinium 
thiocyanate-phenol-chloroform method exactly as previously de- 
scribed  (16). 
PCR.  10 #1 of the DNA samples derived from sera or PBMC 
were amplified in a 100-#1 reaction volume with reagents (Gene- 
Amp; Perkin Elmer Cetus Instruments, Norwalk, CT). Pairs of 
oligonucleotide primers were synthesized on a DNA synthesizer 
(model 308B; Applied Biosystems, Inc., Foster City, CA). The direct 
PCR with the primer pair HBV246S (5'-GAGTCTAGACTCGTG- 
GTGGA, position 246-265) and HBV1086AS (5'-GCGAGAAAG- 
TGAAAGCCTG, position 1082-1100) was run in a programmable 
thermal cycler (Twin Block System; Ericomp, Inc., San Diego, CA) 
under the following conditions: 1 cycle of 5 min denaturation at 
93~  2 min annealing at 56~  3 min elongation at 72~  35 
cycles, in which the denaturation time was decreased to 30 s, the 
annealing time to 30 s and the elongation time to 1 min, followed 
by a 4-rain elongation step at 72~  For the nested PCR,  10 #1 
of the mixture resulting from the direct reaction was amplified with 
the primer pair HBV370S (5'-TATCGCTGGATGTGTCTGC, po- 
sition 370-388) and HBVSIAN (5'-TTTAGAGAGTAACCCCATCT, 
position 851-870) under the same conditions. To sequence the part 
of the HBV genome containing the HBVcore18-27 epitope, selected 
samples  were amplified  with primers HBVXISE (5'-CAAGGT- 
CTTACATAAGAGGA,  position  1641-1660)  and  HBV2627AS 
(5'-CCTGGCAGGCATAATCAATT, position 2627-2646)  in the 
direct PCK and with primers HBVX2SE (5'-CI~TTGGACTCT- 
CAGCAATG, position  1661-1680) and HBVCBHINT (5'-TTG- 
CCTGAGTGCAGTATGGTGAGG, position  2046-2069) in  the 
nested PCR using the same PCR program. Extensive precautions 
were taken to eliminate sources of DNA contamination, as previ- 
ously described  (16). 
Direct Sequencing of  PCR Products.  Direct sequencing of the PCR 
products was performed with the PCR product-sequencing kit (Se- 
quenase~; Amersham/USK Arlington Heights, IL) with the HBV- 
specific primers HBV370S, HBVSIAN, and CBH-INT. As shown 
by others (17), a viral subpopulation as low as 10% of the total 
population can be detected by direct sequencing of PCR products. 
Reverse Transc@tase PCR.  Approximately 1 #g of RNA de- 
rived from each PBMC preparation was used for eDNA synthesis. 
The reaction was performed with oligo dT primer for 1 h at 42~ 
as previously described with and without reverse transcriptase  (16). 
HBV-specific cDNA sequences were amplified with PCR primers 
HBVXISE  and  HBV  1880AS  (5'-GCACAGCTTGGAGGCTT- 
GAA, position 1861-1880) and nested PCR primers HBVX2SE and 
HBV1860AS (5'-CAGTAGGACATGAACAAGAG,  position 1841- 
1860) under the same PCR cycles described above. 
Detection of  AmplifiedDNA.  20-#1  aliquots of the products from 
direct or nested PCR amplifications  were analyzed by electropho- 
resis on a 0.9% agarose gel in the presence of 0.5 #M of ethidium 
bromide. DNA bands were visualized  by UV fluorescence.  For 
Southern blot analysis, the PCR-amplified DNA was transferred 
by capillary transfer to a nylon membrane (Hybond-N; Amersham 
Corp.) and hybridized with a HBV-specific DNA probe (32p la- 
beled by nick-translation) as previously described (18). The mem- 
branes were exposed to an X-ray film (XAR; Eastman Kodak Co., 
Rochester, NY) with an intensifying screen. 
Results 
Selection of Peptide Sequences Coded by the HBV Polymerase 
ORE  We screened the sequence of the HBV polymerase 
protein for the presence of 9-mers  and  10-mers containing 
HLA-A2-specific binding motifs (19). This search yielded 220 
candidate peptides.  Out of this group, we sdected 44 pep- 
tides because they were conserved in at least four of the seven 
HBV adw sequences present in the GenBank data base, and 
since the adw subtype of HBV is prevalent in our patient popu- 
lation.  15 of these peptides were selected for further analysis 
(Table 1) because they displayed an HLA-A2.1-binding affinity 
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Amino acid  Total 
Peptide  sequence  (20) 
Frequency in HBV subtypes 
adw  ayw  adr  ayr 
(7)  (5)  (7)  (1) 
HLA-A2.1  - 
binding 
affinity 
(IC50 nM) 
Acute HBV 
patients 
Tested  responders 
Pols27-s3s  LLAQFTSAI  1  9  6 
PolsTs-Ss3*  FLLSLGIHL  19  6 
POIs16-S24*  SLYADSPSV  8  4 
Pols02-sl0  KLHLYSHPI  19  6 
Po16ss-663*  ALMPLYACI  19  6 
Pols51-ssg*  YMDDVVLGA  18  5 
Pols04-s12  HLYSHPIIL  16  4 
POLss-463*  GLSRYVARL  11  7 
Pols26-s3s  FLLAQFTSAI  19  6 
Pol149qss  YLHTLWKAGI  20  7 
Po1772-780  WILRGTSFV  16  6 
Po1773-7s2*  ILRGTSFVYV  16  6 
Po1765-774  LLGCAANWIL  16  6 
Po1424-432  NLSWLSLDV  18  5 
Core18-27"  FLPSDFFPSV  9  5 
Env335-343*  WLSLLVPFV  20  7 
5  7  1  50  2  0 
5  7  1  10  9  6 
4  0  0  14  9  3 
5  7  1  17  3  0 
5  7  1  25  5  2 
5  7  1  31  7  2 
4  7  1  38  2  0 
4  0  0  71  9  6 
5  7  1  70  2  0 
5  7  1  89  3  0 
5  4  1  278  4  0 
5  4  1  313  7  3 
5  4  1  357  2  0 
5  7  1  385  3  0 
4  0  0  3  9  4 
5  7  1  7  9  6 
* Epitopes, that is, peptides to which at least one of the patients responded. 
(corresponding to an IC50 of <500 nM), which we have re- 
cently shown to be a threshold below which most peptides 
are not immunogenic (20).  2 peptides that have previously 
been shown to be HLA-A2-restricted CTL epitopes (4,  8) 
derived from the core (HBc18-27)  and envelope  (HBs 335- 
343) proteins, were also included for the sake of comparison. 
Analysis of the CTL Response to HBV Polymerase Peptides 
Containing the HLA-A2 Binding Motif.  PBMC from 9 pa- 
tients with acute hepatitis B were stimulated with three or 
more of the polymerase peptides.  Two patients were tested 
serially for 18 mo during and after clinical recovery from acute 
hepatitis and complete seroconversion.  For comparison, we 
also tested 9 HLA-A2 + patients with chronic hepatitis B and 
10 healthy, uninfected control subjects. 
Eight of the nine acutely infected patients responded to 
at least one of the polymerase peptides and, as can be seen 
in Fig. 1, six of the peptides were recognized by at least one 
patient. These results demonstrate the polyclonality and mul- 
tispecificity of the CTL response against the polymerase pro- 
tein during acute viral hepatitis, similar to what we observed 
for core- and envelope-specific CTL responses. Indeed, seven 
of these patients also recognized one or both of the two con- 
trol peptides HBV core18-27  and HBV env335-343,  while 
one patient (A-5) recognized only HBV env335-343.  Only 
one of the acutely infected patients failed to respond to all 
of the peptides in this panel. 
In contrast, none of the uninfected controls responded to 
any of the peptides used in this study (Fig.  1),  suggesting 
that the CTL responses observed in the acutely infected pa- 
tients represented in vitro secondary responses resulting from 
exposure to infected cells in vivo. Furthermore, none of the 
nine patients with chronic hepatitis produced a response. 
As shown in Table 1,  the HLA-binding affinity for four 
of these six peptides (marked with an asterisk) is high, that 
is, the IC50 is <50 nM, suggesting a direct relationship be- 
tween HLA-binding affinity and immunogenicity  even among 
this group of relatively high-affinity peptides. 
It is important to note that we may have underestimated 
the number of CTL epitopes in our panel of peptides be- 
cause several peptides were tested in only two to three pa- 
tients due to limited quantities of PBMC in several patients. 
Accordingly, when limited numbers of PBMC were avail- 
able, polymerase peptides that were shown to elicit a response 
in previously tested patients were preferentially used. 
CD8 + CTL Lines and Clones Specific  for PoI4ss-463, Polsys-s83, 
and Po1816-s24  Recognize Endogenously Synthesized Polymerase 
Antigen.  Two HLA-A2 + patients (A-1 and A-2) with acute 
hepatitis who responded particularly strongly to I>o1575-583, 
PO1455-463, and  Po1816-824 (Fig.  1)  were  chosen  for  further 
analysis. After 2 wk of in vitro stimulation, selected cultures 
that displayed peptide-specific  CTL responses were enriched 
for CD4 + and CD8 + subsets by panning, restimulated in 
vitro with peptide and finally tested for recognition of en- 
dogenously processed polymerase antigen. As shown in Fig. 
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Figure  1.  HBV specific CTL response in pa- 
tients with acute hepatitis (A-I-A-9), chronic 
hepatitis  (C-1-C-9),  and  normal  subjects 
(N-I-N-9). PBMC were stimulated with 10 
#M of peptide for 2 wk as described in Materials 
and Methods and tested in a 4-h 51Cr release 
assay against JY target cells prepulsed overnight 
with the same peptide. Peptide-specific cyto- 
toxicity was measured by subtracting the SlCr 
release by JY target cells not prepulsed with 
the peptide from the SlCr release by JY target 
cells prepulsed with  10 #M  of the peptide. 
Results shown represent percentage of specific 
lysis in a 4-h slCr release assay at an E/T ratio 
of 50:1. The peptide specificity is as follows: 
1, I)o1455-463; 2, I)o1551-559; 3, Po1575-583; 
4, Po1655-663; 5, Po1773-782; 6, Po1816-824; 
7, Core18-27;  8, Env335-343 (see Table 1 for 
the characteristics  of these  peptides), n,  not 
tested. 
2, only the CD8 § fraction of each cell line recognized target 
cells either pulsed with peptide or stably transfected  with 
the polymerase expression vector. These results suggest that 
these three peptides represent native epitopes produced by 
the cellular processing of the endogenously synthesized poly- 
merase protein and recognized in the context of class I HLA 
molecules by CD8 + CTL. 
To obtain pure CD8 + cell lines and further characterize 
these T cell responses, each of the three responding cell lines 
was cloned by limiting dilution in the presence of anti-CD3, 
irradiated  allogeneic  PBL,  and IL-2. All of the derivative 
cytotoxic lines were highly enriched in CD8 + cells as de- 
termined by FACS  ~ analysis (Fig. 3).  Furthermore, five of 
the six Po14ss-463-specific  CTL clones derived in this manner 
also consisted of CD8 + cells, except for one clone from pa- 
tient A-2 (clone 48) that was found to be CD4 +. Unfortu- 
nately,  this clone was  lost before additional studies were 
possible  (Fig.  3). 
Four highly cytotoxic long-term CTL lines and two clones 
specific for Po14ss-463-pulsed targets were chosen for further 
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Figure 2.  CD8  +  cells  recognize endogenously synthesized antigen in 
target cells sharing the HLA-A2 allele. Epitope-specific lines were gener- 
ated by stimulating  PBMC from patient A-1 with 10/+M of the individual 
peptide for 3 wk, with weekly restimulation as described in Materials and 
Methods. On day 15, CD4 + (positive selection) and CD8 + (negative se- 
lection) -enriched lines were generated from the original bulk culture by 
panning+ FACS  |  analysis showed an average enrichment of the selected 
subset by a factor of 3. Results shown represent percentage of specitic lysis 
in a 4-h saCr release assay at an E/T ratio of 30:1. Targets 0Y-EBV) were 
either pulsed with 10/+M of the corresponding peptide overnight or stably 
transfected with the origin for plasmid replication (EBO) polymerase ex- 
pression vector. 
analysis (Table 2 and Fig. 3). The quality of the cytotoxic 
activity was assessed by varying both the amount of peptide 
used to pulse the target cells and by the E/T ratios. Target 
cells pulsed with as little as 0.01 #M of peptide (Table  2) 
were efficiently lysed. Both peptide pulsed and Vpol-infected 
target cells at E/T ratios as low as  1.6:1 (Fig. 3) were also 
efficiently lysed, confirming the ability of these CTL to recog- 
nize endogenously synthesized antigen. Control target cells 
pulsed with no peptide (Table 2) or with an irrelevant pep- 
tide (Table 3), which is an HLA-A2-restricted epitope in HCV- 
infected patients (21), were not lysed, nor were cells infected 
by Wt-vaccinia virus used as control. 
HLA  Restriction Analysis and  Fine Specificity of HBV 
Polymerase-specific  Lines and Clones.  To identify the restric- 
Table  2.  Recognition  of GLSRYVARL-pulsed JY.EBV by 
CTL Is Peptide Dose Dependent 
Peptide  "  *  concentrauon 
Patient  Line  10  1  0.1  0.01  0 (/~M) 
(% cytotox~ity) 
A-1  67-68  41  26  19  13  5 
A-2  10  75  56  52  25  12 
A-2  30  69  40  40  19  6 
* JY target cells were pulsed with GLSRYVARL at the indicated con- 
centrations  to generate target  cells as described in the text. 
Line 12  Line 6  Clone 34 
CD8 98% CD4 0.1%  CD8 62% CD4 19%  CD8 95% CD4 0.8% 
100  r  100  r-~ 
Patient 
A-1  6o I-  ,J.ll~-I  60~e~ 
4o  4o IP 
0  25  50  100  0  25  50  100  0  25  50  I00 
o  Line 55  o  Line 10  o  Clone 48 
.~.  CO8 98% CO4 0.1 ~  CO8 82% CD4 11 '/o  CO8 4 Yo CO4 94% 
lOO [-  1oo  [-  so l- 
t'/)  82 ~-  ,,..,,,,..~  80 L  ~  40~ 
col- F  aoF 
P='.n' 
o~ 
0  25  50  0  25  50  0  25  50 
Effector : Target Ratio 
Figure 3.  CTL response to Po14ss- 
463  GLSRYVARL.  Epitope-specific 
lines and clones, generated by stimula- 
tion of PBMC from patients A-1 and 
A-2 with Pol4ss-~3 peptide, were gen- 
erated  as  described in Materials and 
Methods  and tested  at  varying  E/T 
ratios  against  target  cells 0Y-EBV), 
pulsed  with 10/~M of the corresponding 
peptide (m) overnight or i~ected with 
recombinant Vpol (A), in a standard  4-h 
s~Cr release assay. Wild-type vaccinia 
virus (A) or JY-EBV peptides without 
peptide (O) were used as a control. 
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Target peptide* 
Inducing peptide*  GLSRYVARL  GLPRYVARL  SGLSRYVARL  GLSRYVARLS  KLVALGINAVS 
(%  specific cytotoxicity) 
GLSRYVAILL  54  18  40  41 
GLPRYVAP,  L  1  0  1  0 
SGLSRYVAP,  L  0  0  0  0 
GLSRYVARLS  1  1  0  0 
*  Pohsv463-variant peptides used to stimulate  PBMC. 
* JY target  cells pulsed with indicated peptides at  10/~M. 
S This peptide,  derived from the HCV NS3 protein, is recognized by HLA-A2-restricted CTL from HCV-infected  patients  (21). 
tion element used by the HBV Po145s-463-specific  CTL, cyto- 
toxic lines and clones from patients A-1 and A-2 were tested 
against allogeneic EBV-B cell lines sharing individual HLA 
class I alleles with the effector cells. As shown in Fig. 4, not 
only is HLA-A2 the sole class I allele shared by these two 
patients, but their CTL only lyse peptide pulsed target cells 
that  share this  allele. We conclude that  Po145~-463-specific 
CTL from both patients  are HLA-A2 restricted. 
Peptides containing COOH-  and NH2-terminal trunca- 
tions and elongations of the Po145s-~3 sequence (GLSRYV- 
ARL) were synthesized to determine the optimal length and 
precise termini of this epitope. As shown in Fig. 5 A, trun- 
cation of glycine  455  or leucine  463  greatly reduced the 
HLA-A2-binding affinity of the peptides and totally abrogated 
their recognition by CTL induced by the original peptide 
Po1455463. Interestingly, elongation of the peptide by adding 
a single  serine  residue  normally present  upstream  of the 
Patient A-1  HLA-A2, .424, B51, Bw53, Cwl) 
SO  100  0  60  100  0 
% Specific Cytotoxlclty 
Patient A-2 (HLA-A2, Aw68, B44, Bw54, Cww  Cw7) 
so  100 
A2 
A2, Cw7 
A2 Cw7" 
Figure 4. 
50  lOO  so  lOO 
% Specific Cytotoxlclty 
HLA restriction of epitope Pol4ss~3. PoL,  ss~3-specific lines 
from  patients  A-1 and A-2, generated by stimulation with  10 #M of 
Pol4ss-~3 peptide,  were tested  against allogeneic, partly  HLA-matched 
EBV-B cells prepulsed overnight with 10 #M of the same peptide. Sharing 
HLA class I at other loci did not render target cells susceptible to lysis. 
Cytotoxicity was measured at an E/T ratio of 50:1 in a 4-h 5;Cr release 
assay. The asterisk marks an EBV-B cell line from a separate donor. 
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NH2 terminus or downstream of the COOH  terminus of 
Pohss~3 did not diminish its recognition by CTL (Fig.  5 
A) and may have even increased recognition, despite the fact 
that the HLA-A2-binding ai~nity of the extended peptides 
was reduced 4-10-fold relative to the original peptide (Fig. 
5 A). Despite this, the extended peptides were unable to in- 
duce  a CTL  response  in  a patient  who  responded  quite 
vigorously to the Po14ss-463 sequence (Table 3). Collectively, 
75 
60 
26 
A  ~  B 
so 
26 
o 
0.1  1  10  100  0.1  1  10  100 
PeptMe C,  on(~iUon  (pM) 
HLA-A2.1  HLA-A2.1 
Binding Affinity  Binding Affinity 
Peptide  [iC50 nM]  Pepttde  [IC50 nM] 
O  G/.Sm~ARL  71  O  QL~rYVARL  71 
[]  SGLBRYVARL  2,3111  ~  GLPRYVARL  388 
￿9  aLSRYVARLS  877  0  QUmYWCL  110 
A  I.SRYVARL  80,000  ￿9  GVSRYVARL  1613 
￿9  GLSt~AR  >SO,  O00 
Figure 5.  Recognition of truncated or elongated (A) and variant (B) 
peptides by Pol4ss~3-specific  CTL lines, generated by weekly stimulation 
of PBMC from patient  A-1 with peptide Po1455~63 for 4 wk. Cytotox- 
icity was measured at an E/T ratio  of 50:1 in a 4-h slCr release assay 
against JY-EBV cells prepulsed with varying amounts of the same peptide 
overnight. The sequence GLSRYVAR.L is present in 7/7 HBV subtype 
adw sequences, 4/5 ayw, 0/7 adr, and 0/1 ayr sequences, GLPRYVARL 
is present in 6/7 adr and 1/1 ayr sequences, GLPR.YVVCL is present in 
1/7 adr, and GVSRYVARL is present in 1/5 ayw sequences. The HLA- 
A2.1-binding affanity is calculated as the amount of test peptide needed 
to inhibit the binding  of the radiolabeled HBVcore 18-27 (FLPSDYFPSV) 
peptide by 50%  (IC50). Figure  6.  Time  course  of  CTL response  after 
acute hepatitis B (patient A-l). At each time 
point, PBMC were stimulated with individual 
peptides for 2 wk and cytotoxicity  was measured 
at an E/T ratio of 50:1 in a 4-h 51Cr  release  assay 
against JY-EBV cells prepulsed overnight with 
10/~M of the same  peptide. Serological  and viro- 
logical analysis was performed as described in 
Materials and Methods. Serum ALT activity is 
shown as bars. At each time point shown after 
December 1992, transaminase levels  were  found 
to be normal. 
these data strongly suggest that the GLSRYVARL sequence 
in Po1455-463  represents  the minimal  optimal  epitope recog- 
nized by these CTL.  If one assumes that the density of the 
extended peptides at the surface of APC is lower than  the 
density of the shorter peptide, due to differences in HLA-A2- 
binding affinity,  perhaps the inability of the extended pep- 
tides to induce a CTL response, while they are quite capable 
of being recognized by preexisting CTL at the same peptide 
concentration,  reflects the fact that higher determinant den- 
sities are required for CTL induction than for recognition (22). 
HBV Subtype Specificity of Cytotoxic T  Cell Clones Recog- 
nizing Po14ss-463.  The GLSRYVAR.L sequence is present in 
7/7 and 4/5  HBV adw and ayw subtype sequences, respec- 
tively, present in the GenBank data base. The amino acid se- 
quence  of  the  remaining  ayw  isolate  in  the  data  base  is 
GVSRYVAILL. The sequence of 6/7 adr and 1/1 ayr isolates 
is GLPRYVARL and the sequence of the remaining adr iso- 
late is GLPRYVVCL. Direct sequencing of the viral DNA 
amplified from the serum of five of the nine patients  (A-l, 
A-2, A-6, A-7, and A-9) with acute hepatitis B by nested PCR 
demonstrated  that  the deduced HBV amino  acid sequence 
was identical  to GLSRYVARL in these patients.  Interestingly, 
two of those patients  (A-7 and A-9)  did not mount a CTL 
response to  GLSRYVARL.  These  results  suggest  that  the 
failure of patients A-7 and A-9 to respond to this epitope is 
not  due to  viral variation  within  the epitope.  HBV DNA 
sequence analysis  could not be performed in the other four 
patients because two of them had already cleared the HBV 
DNA at  the time of presentation,  and  serum  was not  ob- 
tained  from  the  other  two. 
Peptides containing the sequences of the different viral sub- 
types were tested for recognition by GLSRYVARL-stimulated 
PBMC to assess the possible cross-reactivity of the CTL re- 
sponse.  All of the variants  were less  efficiently recognized 
than  the prototype sequence against  which  the CTL were 
raised.  Most notably, GLPRYVVCL was not recognized at 
all, even at very high peptide concentration,  despite the fact 
that its HLA-A2.1-binding affinity is similar to that of the 
prototype peptide GLSRYVARL (Fig. 5). This suggests that 
serine 457, alanine 461, and arginine 462 may represent TCR 
contact  sites  (epitope residues) in  this peptide. 
The GVSRYVARL variant, which contained a single sub- 
stitution  at  leucine  456,  a presumptive  HLA contact  site 
(agretope residue), was very poorly recognized by the CTL, 
commensurate with the ninefold reduction in its HLA-A2- 
binding affinity. Interestingly,  however, the NH2 and COOH 
terminally extended peptides described above were very well 
recognized by the CTL despite the fact that  they displayed 
comparably reduced HLA-A2-binding affinities  (Fig.  5 A). 
These observations suggest that leucine 456 not only serves 
as an agretope residue,  but it may also influence the TCR- 
binding affinity of the peptide, perhaps by exerting confor- 
mational influences on serine 457, the adjacent putative TCR 
contact  site. 
HBV DNA Can Persist  in the Serum and PBMC Long After 
Complete Recovery  from Acute Viral  Hepatitis Despite a Vigorous 
Concurrent Polyclonal HBV-specific CTL Response.  In  serial 
studies of two patients,  we demonstrated that  the CTL re- 
sponse to multiple HBV epitopes begins very early and can 
persist for an extended period after complete clinical and sero- 
logical recovery. Both patients Aol (Fig.  6) and A-2 (Fig.  7) 
recovered from acute hepatitis B within a month after onset 
of disease as determined by normalization of liver enzymes. 
Serological recovery was evident by the prompt loss of HBsAg 
and HBeAg and the development of the corresponding anti- 
bodies between 1 and 6 mo after disease onset. However, more 
in-depth molecular and immunological analysis revealed major 
differences  between these two patients. 
For example, patient A-1 failed  to clear HBV DNA from 
his  serum  and HBV DNA  and  RNA from his PBMC for 
1054  CTL Response to Hepatitis B Virus Polymerase Figure  7.  Time  course of CTL response  after acute hepa- 
titis B (patient A-2). At each time point, PBMC  were stimu- 
lated with individual peptides for 2 wk and cytotoxicity  was 
measured at an E/T ratio of 50:1 in a 4-h StCr release assay 
against JY-EBV  cells  prepulsed overnight with 10/zM of the 
same peptide. Serological and virological analysis was per- 
formed as described  in Materials and Methods. Serum ALT 
activity'is shown as bars. At each time point after the initial 
one in November  1992, transaminase levels  were found to be 
normal. 
up to 18 mo after resolution of his liver disease,  despite the 
fact that  he displayed a vigorous,  polyclonal CTL response 
to four different CTL epitopes in the polymerase, envelope, 
and nucleocapsid proteins (Fig. 6) during the first 12 mo of 
his recovery. Eventually, the CTL response waned in this pa- 
tient despite the persistence of viral DNA in his serum. Im- 
portantly,  the deduced amino acid sequence for these three 
epitopes (Poi45s-463, Env335-343, and Corels-27) was identical in 
early and late samples,  suggesting that viral persistence was 
not due to the selection of mutant viral genomes by the strong 
CTL  response in  this patient,  and  that  the waning  of the 
response was not due to the failure of the virus to encode 
the corresponding  epitopes. 
In contrast  to patient  A-l,  all viral markers  cleared very 
rapidly in patient A-2. This patient also displayed a vigorous, 
polyclonal CTL response to the same antigens  early in the 
course of his infection that persisted for >6 mo after recovery 
and eventually waned (Fig.  7).  These results illustrate  that 
HBV-specific CTL,  presumably memory T  cells,  remain in 
the circulation  for an  extended but finite time period after 
all  traces of virus  have  disappeared  from peripheral  blood. 
Discussion 
We have previously demonstrated that patients with acute 
HBV infection develop HLA class 1-restricted CTL responses 
to the viral nucleocapsid and envelope epitopes by stimulating 
their PBMC with sets of long (15-20 mers) overlapping syn- 
thetic peptides. This strategy was inherently rather inefficient, 
and it was necessary to screen very large numbers of peptides 
in many patients in order to identify a small number of epi- 
topes (8).  In  each case,  the inducing  peptides were shown 
to contain shorter (9-11 residues) subunits that actually rep- 
resented  the  minimal,  optimal  epitopes recognized by the 
CTL,  and these subunits were shown to contain allele-spe- 
cific binding  motifs for HLA-A2 (6,  8),  HLA-A31  (7),  or 
HLA-Aw68 (7). 
Based on these observations,  we subsequently improved 
the  efficiency of this  technique  by  starting  with  peptides 
that  contain  specific HLA-binding motifs and limiting  the 
analysis to subjects who express the corresponding allele (8). 
In  the  current  study,  we  further  refined  this  strategy  by 
selecting peptides based on two additional parameters:  high 
sequence conservation and high HLA-binding affinity.  The 
first parameter increases  the likelihood that the subject will 
have been primed to the corresponding epitope in vivo, espe- 
cially if one is studying  the CTL response to viruses with 
high mutation rates,  such as HBV. The second parameter is 
based on the recently demonstrated direct correlation between 
immunogenicity  and  HLA-binding  affinity (20). 
We now report the successful use of this new strategy to 
efficiently study the HLA-A2-restricted CTL response to the 
HBV polymerase protein in patients with acute viral hepa- 
titis. We started by scanning the aligned amino acid sequences 
of 20 HBV genomes whose DNA sequence is contained in 
the  GenBank  data base for peptides  containing  the  HLA- 
A2.1-binding motif (i.e., 9-reefs and 10-mers containing leu- 
cine, methionine, or isoleucine in position 2 and valine, isoleu- 
cine,  or leucine at  the  COOH  terminus),  using  a custom 
computer program we developed for this purpose. This search 
of the 833-residue polymerase protein revealed 220 candidate 
peptides for CTL  analysis. 
Given the limited amount  of blood that  can be ethically 
obtained from an acutely infected patient and the large number 
of lymphocytes (4  ￿  10  6) that  are used to screen  each pep- 
tide (8), only a handful of peptides can be analyzed in each 
patient. For this reason, we limited our analysis to those pep- 
tides that were highly conserved among the seven HBV iso- 
lates of the adw subtype present in our data base, since  this 
subtype is prevalent  in our patient  population.  44 peptides 
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HBV adw isolates were then analyzed for their HLA-binding 
affinity via a direct binding assay. 15 of these 44 peptides dis- 
played HLA-A2.1-binding affinities  of <(500 nM. Based on 
the results of a concurrent study in which we demonstrated 
that an affinity threshold of ~500 nM appears to be associated 
with the capacity of peptide epitopes to elicit CTL responses 
(20),  these 15 peptides were selected for further analysis. 
6 of the 15 polymerase peptides studied (40%) were found 
to be capable of eliciting a CTL response in patients with 
acute viral hepatitis (Table 1), and the CTL response to three 
of these epitopes was characterized in greater detail. Based 
on the success of this strategy, we believe that it will be gener- 
ally useful for the analysis  of the CTL response to  many 
different antigens. 
Several important aspects of this study deserve emphasis. 
First,  the peptide-based in vitro stimulation protocols used 
detect HBV polymerase-specific CTL that were primed in 
vivo,  since we observed CTL responses  only in acutely in- 
fected patients and not in uninfected controls (Fig.  1). This 
is consistent with our earlier studies of the peptide-activated 
CTL response to the HBV nucleocapsid (5, 7) and envelope 
(8)  antigens.  Furthermore,  the Po14ss-463-specific CTL  are 
effective  at  low  (1.6:1)  E/T  cell ratios  (Fig.  3),  and  they 
kill targets pulsed with low (10 riM) peptide concentrations 
(Table 2),  compatible with a physiological role for this re- 
sponse in vivo. 
Second,  the Po145s-463-, Pols75-ss3-, and  Pols16-s24-specific 
CTL responses  are principally mediated by CD8 + T  cells 
(Figs. 2 and 3), and the Po14ss-463-specific  response in patients 
A-1 and A-2 was formally shown to be HLA-A2.1 restricted 
(Fig. 4), also in keeping with our previous studies (4-7). In 
fact, the responses in most patients appear also to be HLA- 
A2.1 restricted, since this is the only class I allele that they 
share with the JY target cell line (HLA-A2.1, B7, Cw7) we 
used in our study. It is interesting that one of the Po14ss-463- 
specific CTL clones derived from patient A2  was CD4 § 
This peptide also contains HLA DR.1- (23), DR4- (24), DR7- 
(25),  DR11-  (26),  and DQ3.1-  (27) binding motifs which 
might be able to induce a class II-restricted response in this 
patient  whose  class II  phenotype  is  DR0101,  DRl104, 
DQ0501,  DQ0301.  Unfortunately, this clone was lost be- 
fore it could be analyzed further. 
Third, Po1455~63, Po1575-ss3 and PO1816-824  epitopes appear to 
represent naturally processed viral  epitopes  since peptide- 
activated CTL recognized endogenously synthesized poly- 
merase antigen expressed by target cells, either stably trans- 
fected with a polymerase-EBV construct (Fig. 2) or infected 
with a polymerase-encoding vaccinia virus (Fig.  3).  Thus, 
CTL specific for these epitopes should be able to recognize 
infected hepatocytes, and therefore could play a role in viral 
clearance and liver cell injury in vivo. 
Fourth, as observed in other viral infections (10,  11), the 
HBV polymerase appears  to be quite immunogenic at the 
CTL level, since it is present in infected cells in trace quanti- 
ties compared with structural proteins but induces an equiva- 
lent CTL response.  It is interesting to note that the poly- 
merase is rapidly degraded from its COOH terminus, where 
most of the epitopes we identified in this study are located, 
perhaps facilitating efficient processing of epitopes located in 
this region of the protein. Since the polymerase enzyme is 
required for the earliest steps in the viral life cycle, polymerase- 
specific CTL may play an important role in limiting viral 
spread and may thereby attenuate disease  severity.  Perhaps 
the fact that most individuals who are infected by HBV de- 
velop a relatively mild, often subclinical,  transient infection 
is due in part to the CTL response to this early antigen. It 
will be necessary to examine patients during the incubation 
phase of HBV infection to determine if there is a temporal 
hierarchy in the timing of the CTL response to each of the 
viral antigens. 
Fifth, unlike the vigorous polymerase-specific CTL response 
we observed in acutely infected patients who cleared the virus, 
we were unable to detect a response in patients with chronic 
HBV infection (Fig. 1). This is consistent with our previous 
observations relating to nucleocapsid- and envelope-specific 
CTL responses (5, 8). It has to be noted, however, that HBV 
envelope-specific CTL have been detected in the intrahepatic 
lymphomononuclear cell infiltrate in patients with chronic 
hepatitis (27),  but not in the peripheral blood.  Therefore, 
while the CTL response is weaker in such patients relative 
to patients with acute hepatitis, it is not completely absent. 
Thus, a vigorous CTL response to these antigens may lead 
to viral clearance, perhaps by destruction of infected hepato- 
cytes. A weak response could cause an indolent necroinflamma- 
tory liver disease by destroying some infected cells but leaving 
others to produce new virus and maintain the infection. We 
have recently reported, in a transgenic mouse model system, 
that class I-restricted CTL can noncytolytically downregu- 
late HBV gene expression when they are activated by antigen 
recognition in vivo, and we have shown that they do so by 
an IFN-y-dependent mechanism (3). 
Sixth, in studies of truncated and extended homologues 
of one of the polymerase epitopes (GLSRYVARL),  we demon- 
strated that this peptide, which was selected for analysis based 
on the HLA-A2-binding motif, actually represents the min- 
imal, optimal epitope sequence recognized by these CTL (Fig. 
5 A). This confirms our earlier studies with long peptides 
containing an internal HLA-A2-binding motif to induce a 
CTL response in which we demonstrated that optimal CTL 
recognition and induction was achieved with truncated pep- 
tides that precisely matched the predicted binding motif (4-7). 
Although the GLSRYVARL epitope is present in all seven 
cloned HBV adw isolates  and 4/5 ayw isolates  in the Gen- 
Bank data base, it is not absolutely conserved. As shown in 
Fig.  5,  serine 457 is replaced by a proline (GLPRYVARL) 
in 6/7 adr and 1/1 ayr isolates, while additional substitutions 
are present in 1/7 adr (GLPRYVVCL) and 1/5 ayw (GVS- 
RYVARL) isolates. As shown in Fig.  5 B, none of the sub- 
stituted peptides was recognized as well as the inducing pep- 
tide by GLSRYVARL-specific CTL. GLPRYVARL also failed 
to induce CTL in contrast to GLSRYVARL. The fact that 
GLPRYVVCL  was not  recognized at all,  despite the fact 
that it bound to HLA-A2 with an affinity similar to that 
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461, and or arginine 462 might represent TCR contact sites 
(epitope residues) in GLSRYVARL. Indeed, the variant pep- 
tide containing a proline for serine substitution at position 
457  (GLPRYVARL) is recognized very poorly despite an 
HLA-A2-binding affinity comparable to that of the proto- 
type peptide. It is interesting to note that the variant peptide 
containing a valine for leucine 456 substitution at anchor po- 
sition 2 in the peptide was very poorly recognized by the 
CTL (Fig. 5 B) despite a relatively good HLA-binding affinity. 
It is possible that position 456 may influence not only the 
HLA-A2-binding affinity of the peptide, but it may also affect 
its TCR-binding affinity,  perhaps by influencing the accessi- 
bility of the adjacent  serine 457 to  the TCR. 
Finally,  serial prospective analysis of the clinical,  serolog- 
ical, virological, and immunological responses to acute HBV 
infection in two patients  (Figs.  6 and 7) revealed  the exis- 
tence of distinct response patterns  and illustrated certain aspects 
ofHBV immunobiology that had not been demonstrated pre- 
viously. The CTL response was detectable very early in the 
disease process in both individuals, and it was vigorous, poly- 
clonal, and multispecific, as we have previously reported (4, 
5, 8). Interestingly,  the CTL response lasted for several months 
after complete clinical  and serological recovery in both pa- 
tients (at least 6 mo in patient A-2 and 12-15 mo in patient 
A-l). This probably reflects the persistence of memory CTL 
in the peripheral blood in patient A-2, who displayed no traces 
of HBV very soon after disease onset (Fig.  7), but in the case 
of patient  A-l,  who has not cleared HBV DNA from his 
serum >18 mo after recovery (Fig.  6), it could also reflect 
the ongoing CTL  activation  events. 
While this remains  speculative at present,  the very pro- 
longed CTL response in patient A-l, coincident with the con- 
tinuing persistence of HBV DNA in the serum and the per- 
sistence ofHBV RNA in the PBMC for several months after 
seroconversion, suggests that the CTL response could have 
been maintained in this patient by continued antigenic stim- 
ulation by virus that the CTL could not eradicate. Since DNA 
sequence analysis revealed that epitope mutations did not ac- 
count for viral persistence in this patient,  it is possible that 
the virus could have been seeded into the circulation  from 
infected cells located in immunologically privileged sites that, 
unlike hepatocytes,  are not accessible to the CTL, for example, 
renal tubular epithelial cells, as has been recently demonstrated 
in a transgenic  mouse model (28).  While this event could 
explain sustained CTL response without virus eradication, 
it does not explain why the CTL response eventually waned 
in this patient. The CTL response detected could be merely 
reflective  of the long half-life  of CTL maintained  by con- 
tinuous viral stimulation. Alternatively, the waning response 
could reflect CTL exhaustion in view of the sustained high- 
level CTL  activation  in this patient. 
Whatever proves to be the correct explanation  for these 
interesting observations, this study demonstrates for the first 
time that HBV has the potential to persist indefinitely, albeit 
in trace quantities, in some patients who have otherwise com- 
pletely recovered from acute viral hepatitis, despite the coex- 
istence of a strong, polyclonal, and multislx*cific CTL response. 
This confirms our earlier report of prolonged viral DNA per- 
sistence after acute hepatitis in patients whose CTL response 
was not examined  (16).  This represents  a new category of 
persistent HBV infection that forms a link in the spectrum 
between classic acute hepatitis with complete viral clearance 
and classic chronic hepatitis with persistent high-level hepatic 
infection. 
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